GlycoMimetics' Lead Candidate Data Published In An Online Journal

GlycoMimetics Inc GLYC has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD.
In the manuscript, scientists highlighted an analysis of minimal residual disease (MRD).
The paper's lead author noted that "the combination of uproleselan with a standard salvage regimen of mitoxantrone, etoposide and cytarabine (MEC) demonstrated a substantial improvement in response rate and survival compared to chemotherapy alone."
The paper also confirms that uproleselan can be safely combined with an intensive salvage chemotherapy regimen without adding toxicity in relapsed/refractory and newly diagnosed older AML patients.
Of the 16 evaluable patients, 11 patients (69%) were MRD negative at the end of induction.
Following treatment with MEC plus uproleselan, 31% of patients (17/54) underwent an allogeneic hematopoietic stem cell transplant.
Of the 22 patients achieving CR/CRi, 11 (50%) underwent transplants.
Median overall survival in relapsed/refractory and newly diagnosed AML patients was 8.8 and 12.6 months, respectively.
The addition of uproleselan was associated with low rates of oral mucositis.
Price Action: GLYC stock is down 0.87% at $2.27 during the premarket session on the last check Friday.